FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Exjade (deferasirox) from Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Iron Overload
• Myelodysplastic Syndrome
• Sickle Cell Disease

Drugs mentioned

• Exjade (deferasirox)

Snippet

SUPPL AP for EXJADE (DEFERASIROX)